Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of SR604 Injection in hemophilia A, hemophilia B, and congenital factor VII deficiency
CTR20241608Phase 2Active
- Sponsor
- Shanghai RAAS
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SR604 in hemophilia A, hemophilia B (HB), congenital factor VII deficiency, sponsored by Shanghai RAAS. Started Jun 2024; status: active.
02
Drugs
SR604
03
Conditions
hemophilia Ahemophilia B (HB)congenital factor VII deficiency
Beyond the preview
Go deeper on CTR20241608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241608.